EP2121722A2 - Photoreactive ru (ii) complexes anchored on oligonucleotides, method for obtaining them and use thereof - Google Patents

Photoreactive ru (ii) complexes anchored on oligonucleotides, method for obtaining them and use thereof

Info

Publication number
EP2121722A2
EP2121722A2 EP08717417A EP08717417A EP2121722A2 EP 2121722 A2 EP2121722 A2 EP 2121722A2 EP 08717417 A EP08717417 A EP 08717417A EP 08717417 A EP08717417 A EP 08717417A EP 2121722 A2 EP2121722 A2 EP 2121722A2
Authority
EP
European Patent Office
Prior art keywords
oligonucleotide
oligonucleotides
photoreactive
formula
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08717417A
Other languages
German (de)
French (fr)
Inventor
Eric Defrancq
Cécile Moucheron
Stéphane RICKLING
De Mesmaeker (Kirsch), Andrée
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Libre de Bruxelles ULB
Universite Joseph Fourier Grenoble 1
Original Assignee
Universite Libre de Bruxelles ULB
Universite Joseph Fourier Grenoble 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Libre de Bruxelles ULB, Universite Joseph Fourier Grenoble 1 filed Critical Universite Libre de Bruxelles ULB
Priority to EP08717417A priority Critical patent/EP2121722A2/en
Publication of EP2121722A2 publication Critical patent/EP2121722A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention is related to a compound made of a photoreactive Ru (II) complex bound (anchored) to G- containing oligonucleotides, the method for obtaining them and their use, especially for targeting specific nucleotide sequences involved in hyperproliferative disorder and to avoid their expression in prokariote or eukaryote cells (especially in bacterial cells, plant cells, animal cells, fungi cells, including yeast cells) .
  • a photoreactive Ru (II) complex bound (anchored) to G- containing oligonucleotides the method for obtaining them and their use, especially for targeting specific nucleotide sequences involved in hyperproliferative disorder and to avoid their expression in prokariote or eukaryote cells (especially in bacterial cells, plant cells, animal cells, fungi cells, including yeast cells) .
  • oligonucleotides are in the field of anti-tumoural therapy and possibly prevention.
  • Ru(II) complexes containing at least two Tap (1, 4, 5, 8-tetraazaphenanthrene) ligands are known to be oxidant enough in their excited state to photo-oxidize a guanine unit of DNA molecule (oligonucleotide) ; such a ruthenium complex anchored on one strand of a hybridized oligonucleotide, without guanine, was able to react under illumination with a guanine situated on the complementary strand, which leads to a photocrosslinking of both strands that may be used in anticancer therapy (antisense strategy) .
  • WO 2004/037907 describes luminescent metal ion complexes and components thereof (including oligonucleotides tethered to these complexes) which are useful in detection and isolation of target analytes, such as biomolecules .
  • the European Patent EP 0 733 058 describes the selective modification of nucleic acids at specific sites with redox active moieties, such as transition metal complexes.
  • This European Patent describes an electron donor and/or an electron acceptor moiety that are covalently bound, preferably along the ribose-phosphate backbone of the nucleic acids sequence at predetermined positions.
  • the present invention aims to provide compounds comprising oligonucleotides which are able to lead to photocrosslinking with complementary nucleotide sequences to be targeted and inactivated, and which do not present the drawbacks of the state of the art.
  • a preferred aim of the present invention is to obtain compounds made of oligonucleotides which present a high specificity and are photo-inactivated, if no binding
  • hybridisation with their corresponding specific nucleotide sequences to be targeted has been obtained.
  • a further aim of the present invention is to propose such compound which will reduce the possible side effects of oligonucleotides which are not bound (hybridized) to their corresponding nucleotide sequences, for instance by avoiding any possible binding (hybridization) upon anti- oncogenic sequences, if no binding has been obtained upon targeted oncogenic sequences.
  • the present invention is related to a compound made of an oligonucleotide bound to (linked to or anchored on) a photoreactive Ru (II) complex Ru(Li) (L 2 ) (L 3 ) 2+ wherein Li and L 2 both comprise two pyrazinic moieties coordinated to the Ru(II) center according to formula I
  • Rl and R2 are H or form between them a cycle having the formula II, formula III or formula IV
  • L3 is any a di-imine polyazaaromatic ligand
  • oligonucleotides defined also hereafter as Oligo
  • Oligo oligonucleotides
  • these oligonucleotides are guanine-containing oligonucleotides, which means that these oligonucleotides comprise one or more guanine unit(s) (G base) .
  • the photoreactive Ru (II) complex presenting the formula Ru(Li) (L 2 ) (L 3 ) 2+ comprises at least two ligands selected from the group consisting of the 1, 4, 5, 8, 9, 12-hexaazatriphenylene (dipyrazino (1,3-f) (2', 3'- h) quinoxaline, the 2,2' bipyrazine, the 1,10 phenanthrolino- [5, 6-b] -1,4,5, 8, 9, 12-hexaazatriphenylene or the 1,4,5,8- tetraazaphenanthrene (or pyrazino [2, 3-f] -quinoxaline) .
  • the oligonucleotide sequence of the compound is an antisense or RNAi oligonucleotide sequence (for gene silencing) and made of at least 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, but less than 200, 150, 100, 50, 40 or 35 bases bound (linked or anchored) to the photoreactive Ru (II) complex on the 5' or 3' end (possibly through a linker sequence) .
  • the present invention concerns also the method for obtaining these compounds wherein the binding (linkage or anchorage) between the photoreactive complex and the oligonucleotides is obtained with a chemical linker having a suitable end for allowing the binding to this complex.
  • the present invention is also related to a pharmaceutical composition or a diagnostic kit (kit of parts or apparatus) comprising the compound (II) above described and possibly a photon (hv) or a device that emits photons.
  • the pharmaceutical composition may also comprise an adequate pharmaceutical carrier or diluent.
  • the diagnostic kit (or apparatus) one may also include a device that emits photons.
  • Another aspect of the present invention is related to the compound of the invention combined with a photon (that forms a reactive agent) for use as a medicament.
  • a further aspect of the present invention is related to the use of the pharmaceutical composition for the manufacture of a medicament in the treatment of a disease induced by expression of specific nucleotide sequences, such as an hyperproliferative disorder (i.e. cancer) induced by oncogenes, whose expression should be modulated, preferably decreased or suppressed and that are complementary to the sequences of the oligonucleotides present in the compound of the invention.
  • a disease induced by expression of specific nucleotide sequences such as an hyperproliferative disorder (i.e. cancer) induced by oncogenes, whose expression should be modulated, preferably decreased or suppressed and that are complementary to the sequences of the oligonucleotides present in the compound of the invention.
  • the adequate pharmaceutical carrier of the composition according to the invention or diluent is selected by the person skilled in the art according to the type of administration required upon specific cells or tissues. [0019] The ratio between the amount of the adequate pharmaceutical carrier or diluent and the active compound is defined by the person skilled in the art, according to the administrated doses to be applied to the mammal subject,
  • this adequate pharmaceutical carrier is present in a solid or liquid form and these oligonucleotides are possibly incorporated into suitable vectors (cationic vesicles, plasmid, virus, etc) with adjuvant (s) to transform (transfect) the cells.
  • this pathology is an hyper- proliferative disorder or pathology (cancer) present in specific cells (tumour cells) .
  • This hyper-proliferative disorder or pathology (cancer) treated by the composition of the present invention is a hyper-proliferative disorder or pathology (cancer) , preferably affecting epithelial cells such as epithelial tumoural cells of the skin, of the digestive track (in particular tumours of rectum, colon, intestine, stomach, oesophagus, pharynx, or buccal cavity), tumoural cells of the lung, or tumoural cells affecting a genital or an urinary organ, in particular, the ureter, the urethra, the prostate, the urinary bladder or the uterus neck) or any other tissue that can be treated by the compound of the invention in addition to a photon, or by the device that may enter into a conduct of these organs affected by this tumour.
  • Other examples of cells are prokaryote or
  • the treatment according to the invention comprises the steps of putting into contact the compound according to the invention with the cells to be treated and submitting these cells to an adequate light irradiation (photon emission) .
  • this light irradiation is obtained by any suitable device that emits photons upon the area of the epithelium to be treated.
  • this device emits light in the visible range for a sufficient time for obtaining an efficient treatment of the tumoural cell (through activation of the photoreactive complexes) .
  • the compound and this device could be present in a kit of parts or an apparatus, possibly comprising an endoscope or catheter or any medical device which could be used for obtaining a contact between an epithelium comprising said tumoural cell and the (actived) compound elements of the pharmaceutical composition according to the invention under light irradiation (photon emission) .
  • the present invention will be described in more details in the following non-limited examples, in reference to the enclosed figures.
  • the figures 1 to 3 show different compounds (Ru (II) oligonucleotides) according to the invention.
  • the figure 4 represents a polyacrylamide gel electrophoresis of the different oligonucleotides according to the invention. Denaturating PAGE experiments after 0, 5, 10, 15 and 30 min of illumination: line 1 to 5: WlT* ss line 6 to 10: WlT* hybridized with W3 (WlT ds) line 11 to 15: WlT* and SCl line 16 to 20: WlT* and SC2
  • a compound (photoactive Ru(II) complex containing at least two TAP (1, 4, 5, 8-tetraazaphenanthrene) ligands anchored on an oligonucleotide containing a guanine unit) is used for the specific recognition of an oligonucleotide sequence and the formation, under visible light irradiation, of a photocrosslinking between this Ru-oligonucleotide and its complementary strand.
  • Ru (Tap) 2 Phen 2+ and Ru (Phen) 2 Phen 2+ are chemically bound to the 3' or 5' end of the ODN via an oxime bond.
  • Ru (Bpy) 2 Phen 2+ is obtained by reacting Ru (Bpy) 2 C1 2 with the derivatized ligand Phen" and is anchored to the oligonucleotides derivatized with an aldehyde function.
  • Radiolabelling in 5' position of the ODNs have been realised by treating with T4 polynucleotide kinase and
  • Tris-borate, pH 8, 2 mM EDTA) gel. DNA fragments were visualised by autoradiography with a Storage Phosphor Screen (Amersham) film and were counted with a Phosphor-Imager Storm 860 instrument.
  • the figure 1 shows the different Ru- oligonucleotides that have been synthesized. These Ru-ODNs have been called Waleol if the anchoring of the complex was done on the 3' end and Waleo2 if the anchoring was done on the 5' end. Moreover, if the complex anchored contains Tap ligands, T to the former name was added, if it contains Bpy ligands, a B was added and if it contains Phen ligands, a P was added, so to obtain 6 different Ru-ODNs : WaleolT, Waleo2T, WaleolB, Waleo2B, WaleolP and Waleo2P; Waleo3 is their complementary strand.
  • the oligonucleotide used to support the Ru(II) complex contains a guanine unit which precisely is the base that is oxidized by the photo-oxidizing Ru(II) complexes, if the target complementary strand is not found.
  • WaleolP single stranded and WaleolP double stranded undergoes a hypsochromic effect around 450 nm (MLCT absorption band) and a hyperchromic effect above 500 nm whereas the emission drops during the illumination, which is known to be characteristic of a photodechelation of the Ru(II) complex
  • the origin of the photo-product can be double: either it is an intramolecular photo-product (the Ru (Tap) 2 Phen 2+ complex in its excited state reacts with the guanine of its own ODN strand) or it is an intermolecular photoadduct (the Ru (Tap) 2 Phen 2+ complex in its excited state reacts with the guanine of another Ru-ODN) .
  • the same observations are made from the absorption spectra of the double stranded WaleolT sample under illumination with the only difference that the photoreaction with the single strand is faster than with the double strand (Fig.3).
  • the results obtained with the 5'- modified ODNs are very similar to those described for the 3' - modified ODNs.
  • WaleolT undergoes an intramolecular reaction rather than reacting with a non-recognized guanine.
  • the photo-active molecule does not find its target (its complementary strand) , it kills itself and does not damage any other DNA sequence.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is related to photoreactive Ru (II) complexes anchored on a G- containing oligonucleotide, e.g. compound 1, the method for obtaining them and their use, especially for targeting specific nucleotide sequences that become photocrosslinked to the photoreactive Ru (II) complex anchored to the G- containing oligonucleotide.

Description

PHOTOREACTIVE RU (II) COMPLEXES ANCHORED ON OLIGONUCLEOTIDES, METHOD FOR OBTAINING THEM AND USE THEREOF
Field of the invention
[0001] The present invention is related to a compound made of a photoreactive Ru (II) complex bound (anchored) to G- containing oligonucleotides, the method for obtaining them and their use, especially for targeting specific nucleotide sequences involved in hyperproliferative disorder and to avoid their expression in prokariote or eukaryote cells (especially in bacterial cells, plant cells, animal cells, fungi cells, including yeast cells) .
[0002] A preferred use of these oligonucleotides is in the field of anti-tumoural therapy and possibly prevention.
Background of the invention [0003] Ru(II) complexes containing at least two Tap (1, 4, 5, 8-tetraazaphenanthrene) ligands are known to be oxidant enough in their excited state to photo-oxidize a guanine unit of DNA molecule (oligonucleotide) ; such a ruthenium complex anchored on one strand of a hybridized oligonucleotide, without guanine, was able to react under illumination with a guanine situated on the complementary strand, which leads to a photocrosslinking of both strands that may be used in anticancer therapy (antisense strategy) .
State of the art
[0004] WO 2004/037907 describes luminescent metal ion complexes and components thereof (including oligonucleotides tethered to these complexes) which are useful in detection and isolation of target analytes, such as biomolecules . [0005] The European Patent EP 0 733 058 describes the selective modification of nucleic acids at specific sites with redox active moieties, such as transition metal complexes. This European Patent describes an electron donor and/or an electron acceptor moiety that are covalently bound, preferably along the ribose-phosphate backbone of the nucleic acids sequence at predetermined positions. These complexes possess unique structural features which enable the use of an entirely new class of bioconductors and diagnostic probes. [0006] The publication of Lentzen & al, (Journal of Biological Inorganic Chemistry Volume 9 p. 100-108 (2004)) describes the determination of DNA guanine sites forming photo-adducts with Ru (II) -labeled oligonucleotides. In this publication, the inventors describe oligonucleotides containing photo-reactive Ru (II) complexes for use in antisense strategy. The synthesised oligonucleotides do not comprise any guanine in it, because these Ru(II) complexes are known to be reactive enough in the excited state to photo-oxidize the guanine unit present in the complementary DNA sequence. [0007] The publication of Garcia-Fresnadillo & al (Bio-physical Journal Volume 82 p.978-987 (2002)) describes luminescence quenching of Ru-Labeled oligonucleotides by targeted complementary strands. The probe sequences do not comprise any guanine units in order to avoid a photo-oxidation of one of the guanine unit present in the oligonucleotides probe-sequences .
Aims of the invention
[0008] The present invention aims to provide compounds comprising oligonucleotides which are able to lead to photocrosslinking with complementary nucleotide sequences to be targeted and inactivated, and which do not present the drawbacks of the state of the art.
[0009] A preferred aim of the present invention is to obtain compounds made of oligonucleotides which present a high specificity and are photo-inactivated, if no binding
(hybridisation) with their corresponding specific nucleotide sequences to be targeted has been obtained.
[0010] A further aim of the present invention is to propose such compound which will reduce the possible side effects of oligonucleotides which are not bound (hybridized) to their corresponding nucleotide sequences, for instance by avoiding any possible binding (hybridization) upon anti- oncogenic sequences, if no binding has been obtained upon targeted oncogenic sequences.
Summary of the invention
[0011] The present invention is related to a compound made of an oligonucleotide bound to (linked to or anchored on) a photoreactive Ru (II) complex Ru(Li) (L2) (L3) 2+ wherein Li and L2 both comprise two pyrazinic moieties coordinated to the Ru(II) center according to formula I
Formula 1
Wherein Rl and R2 are H or form between them a cycle having the formula II, formula III or formula IV
and wherein L3 is any a di-imine polyazaaromatic ligand
and wherein these complexes are anchored via L3 to oligonucleotides (defined also hereafter as Oligo) , wherein these oligonucleotides are guanine-containing oligonucleotides, which means that these oligonucleotides comprise one or more guanine unit(s) (G base) .
[0012] According to a preferred embodiment, in the compound of the invention, the photoreactive Ru (II) complex presenting the formula Ru(Li) (L2) (L3) 2+ comprises at least two ligands selected from the group consisting of the 1, 4, 5, 8, 9, 12-hexaazatriphenylene (dipyrazino (1,3-f) (2', 3'- h) quinoxaline, the 2,2' bipyrazine, the 1,10 phenanthrolino- [5, 6-b] -1,4,5, 8, 9, 12-hexaazatriphenylene or the 1,4,5,8- tetraazaphenanthrene (or pyrazino [2, 3-f] -quinoxaline) . [0013] The oligonucleotide sequence of the compound is an antisense or RNAi oligonucleotide sequence (for gene silencing) and made of at least 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, but less than 200, 150, 100, 50, 40 or 35 bases bound (linked or anchored) to the photoreactive Ru (II) complex on the 5' or 3' end (possibly through a linker sequence) .
[0014] The present invention concerns also the method for obtaining these compounds wherein the binding (linkage or anchorage) between the photoreactive complex and the oligonucleotides is obtained with a chemical linker having a suitable end for allowing the binding to this complex. [0015] The present invention is also related to a pharmaceutical composition or a diagnostic kit (kit of parts or apparatus) comprising the compound (II) above described and possibly a photon (hv) or a device that emits photons. The pharmaceutical composition may also comprise an adequate pharmaceutical carrier or diluent. In the diagnostic kit (or apparatus) according to the invention, one may also include a device that emits photons.
[0016] Another aspect of the present invention is related to the compound of the invention combined with a photon (that forms a reactive agent) for use as a medicament. [0017] A further aspect of the present invention is related to the use of the pharmaceutical composition for the manufacture of a medicament in the treatment of a disease induced by expression of specific nucleotide sequences, such as an hyperproliferative disorder (i.e. cancer) induced by oncogenes, whose expression should be modulated, preferably decreased or suppressed and that are complementary to the sequences of the oligonucleotides present in the compound of the invention.
[0018] The adequate pharmaceutical carrier of the composition according to the invention or diluent is selected by the person skilled in the art according to the type of administration required upon specific cells or tissues. [0019] The ratio between the amount of the adequate pharmaceutical carrier or diluent and the active compound is defined by the person skilled in the art, according to the administrated doses to be applied to the mammal subject,
(including a human patient) , the surface of the tumoural epithelium or the volume of the tumour to be treated and the possible side effects of the active compound upon the mammal subject, including a human patient. [0020] Preferably, this adequate pharmaceutical carrier is present in a solid or liquid form and these oligonucleotides are possibly incorporated into suitable vectors (cationic vesicles, plasmid, virus, etc) with adjuvant (s) to transform (transfect) the cells.
[0021] Preferably, this pathology is an hyper- proliferative disorder or pathology (cancer) present in specific cells (tumour cells) . [0022] This hyper-proliferative disorder or pathology (cancer) treated by the composition of the present invention is a hyper-proliferative disorder or pathology (cancer) , preferably affecting epithelial cells such as epithelial tumoural cells of the skin, of the digestive track (in particular tumours of rectum, colon, intestine, stomach, oesophagus, pharynx, or buccal cavity), tumoural cells of the lung, or tumoural cells affecting a genital or an urinary organ, in particular, the ureter, the urethra, the prostate, the urinary bladder or the uterus neck) or any other tissue that can be treated by the compound of the invention in addition to a photon, or by the device that may enter into a conduct of these organs affected by this tumour. Other examples of cells are prokaryote or eukaryotes cells, preferably pathogenic cells to form a reactive agent presenting nucleotides sequences to be targeted for a diagnostic or therapeutic purpose.
[0023] The treatment according to the invention comprises the steps of putting into contact the compound according to the invention with the cells to be treated and submitting these cells to an adequate light irradiation (photon emission) . Preferably, this light irradiation is obtained by any suitable device that emits photons upon the area of the epithelium to be treated.
[0024] Preferably, this device emits light in the visible range for a sufficient time for obtaining an efficient treatment of the tumoural cell (through activation of the photoreactive complexes) .
[0025] Advantageously, the compound and this device could be present in a kit of parts or an apparatus, possibly comprising an endoscope or catheter or any medical device which could be used for obtaining a contact between an epithelium comprising said tumoural cell and the (actived) compound elements of the pharmaceutical composition according to the invention under light irradiation (photon emission) . [0026] The present invention will be described in more details in the following non-limited examples, in reference to the enclosed figures.
Short description of the figures [0027] The figures 1 to 3 show different compounds (Ru (II) oligonucleotides) according to the invention. [0028] The figure 4 represents a polyacrylamide gel electrophoresis of the different oligonucleotides according to the invention. Denaturating PAGE experiments after 0, 5, 10, 15 and 30 min of illumination: line 1 to 5: WlT* ss line 6 to 10: WlT* hybridized with W3 (WlT ds) line 11 to 15: WlT* and SCl line 16 to 20: WlT* and SC2
Detailed description of the invention
[0029] A compound (photoactive Ru(II) complex containing at least two TAP (1, 4, 5, 8-tetraazaphenanthrene) ligands anchored on an oligonucleotide containing a guanine unit) is used for the specific recognition of an oligonucleotide sequence and the formation, under visible light irradiation, of a photocrosslinking between this Ru-oligonucleotide and its complementary strand. The presence of a guanine base in the ruthenium-labeled oligonucleotide sequence implies an intramolecular photoreaction of this Ru-ODN (ODN = oligodeoxyribonucleotide) in the absence of the target sequence, even if it is in presence of any other G containing ODN. This work is the basis of a new type of intelligent drugs called "seppuku molecules", which autodestruct if they do not manage to find their target, leading to a totally non-reactive and non-toxic species.
[0030] Three different Ru(II) complexes anchored on a 14-mer oligonucleotide, either in position 3' or 5' were obtained. The complexes used are Ru (Tap) 2Phen2+ (which is photoreactive with the guanine) and Ru (Bpy) 2Phen2+ and Ru (Phen) 2Phen2+ (wich are not photooxydant enough to react with a G base, under illumination) [Bpy = 2,2' bipyridine, Phen = 1, 10-phenanthroline, Phen" = 5- ( (N- (ter-butoxycarbonyl) -0- (carboxymethyl) hydroxy1amine) glycinamido) -1 , 10- phenanthroline] . Ru (Tap) 2Phen2+ and Ru (Phen) 2Phen2+ are chemically bound to the 3' or 5' end of the ODN via an oxime bond. Ru (Bpy) 2Phen2+ is obtained by reacting Ru (Bpy) 2C12 with the derivatized ligand Phen" and is anchored to the oligonucleotides derivatized with an aldehyde function.
[0031] The single stranded and duplex solutions used for the spectroscopic studies were prepared at a concentration of 1.10"5 M in an aqueous buffer (Tris-HCl 10 mM, NaCl 150 mM, pH = 7) . All the measurements have been realised in 600 μL quartz cells (UV select, 1.0 x 0.2 cm) . Illuminations have been performed with a Thermo Oriel Xe lamp (500W) (Fairlight, The Netherlands) with a H2O and aqueous KNO2 filters. Absorption and emission spectra have been performed on a Perkin-Elmer Lambda 40 UV-Vis spectrometer and a Shimadzu RF-5001PC spectrofluorimeter equipped with a Hamamatsu R928 red- sensitive photomultiplier tube respectively.
[0032] Radiolabelling in 5' position of the ODNs have been realised by treating with T4 polynucleotide kinase and
[β32P] ATP at 37°C for 30 min. Hybridization, when necessary, has been performed by incubating the labeled ODN with its complementary strand at 85°C for 5 min and at room temperature for at least 6 hrs . Illuminations for the PAGE experiments have been performed with a He/Cd laser (442 nm) (Melles Griot) .
[0033] Polyacrylamide gel electrophoresis have been performed through a denaturing (urea 7 M) 20 % polyacrylamide
(19:1 ratio of acrylamide to bisacrylamide) with TBE (90 mM
Tris-borate, pH = 8, 2 mM EDTA) gel. DNA fragments were visualised by autoradiography with a Storage Phosphor Screen (Amersham) film and were counted with a Phosphor-Imager Storm 860 instrument.
[0034] The figure 1 shows the different Ru- oligonucleotides that have been synthesized. These Ru-ODNs have been called Waleol if the anchoring of the complex was done on the 3' end and Waleo2 if the anchoring was done on the 5' end. Moreover, if the complex anchored contains Tap ligands, T to the former name was added, if it contains Bpy ligands, a B was added and if it contains Phen ligands, a P was added, so to obtain 6 different Ru-ODNs : WaleolT, Waleo2T, WaleolB, Waleo2B, WaleolP and Waleo2P; Waleo3 is their complementary strand. The important fact to notice is that the oligonucleotide used to support the Ru(II) complex contains a guanine unit which precisely is the base that is oxidized by the photo-oxidizing Ru(II) complexes, if the target complementary strand is not found.
[0035] The solutions of the different Ru-ODNs were first illuminated in an aqueous buffer and one may observe the evolution of the absorption and emission spectra as a function of the illumination time. 1.10"5 M solutions of single stranded and double stranded Waleolx and Waleo2x (x = T, B or P) were prepared. Illumination of 500 μL of each solution was undertaken and absorption and emission spectra were recorded after 5, 15, 30 and 60 min of illumination. Typical spectra of WaleolPss, WaleolPds, WaleolTss and WaleolTds can be seen on the figures.
[0036] During illumination, the absorption spectrum of
WaleolP single stranded and WaleolP double stranded (ds) undergoes a hypsochromic effect around 450 nm (MLCT absorption band) and a hyperchromic effect above 500 nm whereas the emission drops during the illumination, which is known to be characteristic of a photodechelation of the Ru(II) complex
(Fig.2). In contrast, the absorption spectra of WaleolT ss shows a hyperchromic and hypsochromic effect of the MLCT absorption band around 420 nm. This is characteristic of the formation of a photoadduct ; that means that the Ru (Tap) 2Phen2+ complex anchored on the ODN reacts, under illumination, with a G base. The origin of the photo-product can be double: either it is an intramolecular photo-product (the Ru (Tap) 2Phen2+ complex in its excited state reacts with the guanine of its own ODN strand) or it is an intermolecular photoadduct (the Ru (Tap) 2Phen2+ complex in its excited state reacts with the guanine of another Ru-ODN) . The same observations are made from the absorption spectra of the double stranded WaleolT sample under illumination with the only difference that the photoreaction with the single strand is faster than with the double strand (Fig.3). [0037] The results obtained with the 5'- modified ODNs are very similar to those described for the 3' - modified ODNs. The only difference is in the emission spectrum evolution of Waleo2Tds compared to WaleolTds. Waleo2Tds shows very poor emission compared to WaleolTds and its luminescence does not evolve during illumination. This may result from the direct vicinity of 3 Gs on the extremity of the 3' end of the target strand. The presence of 3 guanines might favour the electron transfer between one of them and the excited ruthenium complex and thereby quenches the luminescence of its excited state. [0038] To check the nature of the photoadduct obtained by illuminating WaleolT alone and in presence of its complementary strand, polyacrylamide gel electrophoresis experiments were performed. [0039] Therefore, 5'-32P labeled WaleolT and WaleolTds solutions were illuminated with a monochromatic laser (λ = 452 nm) during 5, 10, 15 and 30 min (Fig 4) . Lane 1 is the native WaleolT Ru-ODN. During illumination, WaleolT is consumed and a new band appears migrating faster than the starting material (lanes 2 to 5) . This observation is consistent with the hypothesis of intramolecular photoreaction of WaleolT. After 30 min of illumination, 85 % of intramolecular photoproduct were obtained. [0040] When WaleolT is hybridized with its complementary strand and illuminated as described, a new band appears on the electrophoresis gel, migrating much slower than native WaleolT, consistent with a photocrosslinking product (lane 7 to 10). The amount of photocrosslinking is around 40 % of the starting material after 30 min of illumination. On the other hand, no trace of the intramolecular photoproduct can be seen. The compounds WaleolB, Waleo2B, WaleolP and Waleo2P do not give rise to photocrosslinkings in the presence of Waleo3. Thus, WaleolT under illumination undergoes an intramolecular reaction whereas the double strand leads selectively to the photocrosslinking product.
[0041] In a second step, the complementary strand
(Waleo3) were replaced by another ODN strand containing one or more guanine bases in order to check the specificity of the photoactive molecule. Two scramble sequences SCl: 5'-TTT TCG TTT TAA ATT AT-3' with 1 G and SC2 : 5'-TAA ATT TAA GGA AAA AA- 3' with 2 Gs were used. After illumination, PAGE experiments showed absolutely no photocrosslinking product, but only intramolecular photoproduct could be detected (Lane 11 to 20). [0042] In conclusion, WaleolT photoreacts very specifically with its target sequence and leaves all other guanines containing oligonucleotides intact. In the presence of any other sequence than the targeted sequence, WaleolT undergoes an intramolecular reaction rather than reacting with a non-recognized guanine. In other words, if the photo-active molecule does not find its target (its complementary strand) , it kills itself and does not damage any other DNA sequence.

Claims

CLAIMS l.A compound comprising oligonucleotide bound to a photoreactive Ru (II) complex Ru(Li) (L2) (L3) 2+ wherein Li and L2 both comprise two pyrazinic moieties coordinated to the Ru(II) center according to formula I
Formula 1
Wherein Rl and R2 are H or form between them a cycle having the formula II, formula III or formula IV
and wherein L3 is anchored to the oligonucleotide characterized in that the oligonucleotide comprises one or more guanine unit(s) (G base) .
2. The compound according to claim 1, wherein the photoreactive Ru (II) complex is anchored upon the oligonucleotide sequence by a chemical linker.
3. The compound according to any of the claim 1 or
2, wherein the oligonucleotide is an antisense oligonucleotide .
4.A diagnostic kit or apparatus comprising the compound according to claims 1 to 3 and possibly a suitable device that emits photons.
5. The diagnostic kit of claim 4 which further comprises a device that emits photons.
6.A pharmaceutical composition comprising an adequate pharmaceutical carrier or diluent, the compound according to any of the preceding claims 1 to 3, and a photon.
7. Use of the pharmaceutical composition according to claim 6 for the manufacture of a medicament in the treatment and/or the prevention of an hyper-proliferative disorder (cancer) .
8. Use according to the claim 7, wherein the hyper-proliferative disorder is a disorder affecting an epithelial cell.
9. The use according to the claim 8, wherein the epithelial cell is a tumoural cell, selected from the group consisting of a skin tumoural cell, a digestive track tumoural cell, lung tumoural cell and tumoural cell of the reproductive and/or urinary organ of a mammal.
10. The use of claim 8, wherein the mammal is a human .
EP08717417A 2007-03-16 2008-03-05 Photoreactive ru (ii) complexes anchored on oligonucleotides, method for obtaining them and use thereof Withdrawn EP2121722A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08717417A EP2121722A2 (en) 2007-03-16 2008-03-05 Photoreactive ru (ii) complexes anchored on oligonucleotides, method for obtaining them and use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07104297A EP1970378A1 (en) 2007-03-16 2007-03-16 Photoreactive Ru (II) complexes anchored on oligonucleotides, method for obtaining them and use thereof
PCT/EP2008/052667 WO2008113686A2 (en) 2007-03-16 2008-03-05 Photoreactive ru (ii) complexes anchored on oligonucleotides, method for obtaining them and use thereof
EP08717417A EP2121722A2 (en) 2007-03-16 2008-03-05 Photoreactive ru (ii) complexes anchored on oligonucleotides, method for obtaining them and use thereof

Publications (1)

Publication Number Publication Date
EP2121722A2 true EP2121722A2 (en) 2009-11-25

Family

ID=38222216

Family Applications (2)

Application Number Title Priority Date Filing Date
EP07104297A Withdrawn EP1970378A1 (en) 2007-03-16 2007-03-16 Photoreactive Ru (II) complexes anchored on oligonucleotides, method for obtaining them and use thereof
EP08717417A Withdrawn EP2121722A2 (en) 2007-03-16 2008-03-05 Photoreactive ru (ii) complexes anchored on oligonucleotides, method for obtaining them and use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP07104297A Withdrawn EP1970378A1 (en) 2007-03-16 2007-03-16 Photoreactive Ru (II) complexes anchored on oligonucleotides, method for obtaining them and use thereof

Country Status (5)

Country Link
US (1) US20100113572A1 (en)
EP (2) EP1970378A1 (en)
JP (1) JP2010521436A (en)
CA (1) CA2679344A1 (en)
WO (1) WO2008113686A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205455D0 (en) 2002-03-07 2002-04-24 Molecular Sensing Plc Nucleic acid probes, their synthesis and use
WO2022051669A1 (en) 2020-09-04 2022-03-10 AtlasXomics Inc. Methods and devices for spatially encoded biological assays

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591578A (en) * 1993-12-10 1997-01-07 California Institute Of Technology Nucleic acid mediated electron transfer
US6623513B2 (en) * 2001-01-19 2003-09-23 Advanced Photodynamic Technologies, Inc. Apparatus and method of photodynamic eradication of organisms utilizing pyrrolnitrin
WO2004037907A2 (en) * 2002-10-21 2004-05-06 Biosearch Technologies, Inc. Luminescent metal ion complexes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008113686A2 *

Also Published As

Publication number Publication date
US20100113572A1 (en) 2010-05-06
JP2010521436A (en) 2010-06-24
WO2008113686A2 (en) 2008-09-25
CA2679344A1 (en) 2008-09-25
WO2008113686A3 (en) 2009-01-15
EP1970378A1 (en) 2008-09-17

Similar Documents

Publication Publication Date Title
Boutorine et al. Chlorin-oligonucleotide conjugates: synthesis, properties, and red light-induced photochemical sequence-specific DNA cleavage in duplexes and triplexes
Chen et al. A tumor mRNA-triggered photodynamic molecular beacon based on oligonucleotide hairpin control of singlet oxygen production
US12472187B2 (en) Texaphyrin-Pt(IV) conjugates and compositions for use in overcoming platinum resistance
JPH07502749A (en) Compositions and methods for regulating RNA
JP2001316270A (en) Photocleavage of RNA using texaphyrin
CN104780941A (en) Conjugate of a photosensitiser and chitosan and uses thereof
CN115385861B (en) Fluorescent probe and preparation method and application thereof
CN105732681B (en) Fluorescence diagnosis and treatment reagent exploitation and its cell application of the one kind for diagnosing and treating non-small cell lung cancer
CN109593831A (en) A kind of preparation method of the biological sensor of Two-way Cycle based on functionalization graphene quantum dot and double Quenching Systems
CN118930523B (en) Protein anchored copper response photoacoustic probe and preparation method and application thereof
Wang et al. Fluorescent carbon dots with real-time nucleolus-monitoring capability for gene delivery and biosensing of NO2–and pH
US20100113572A1 (en) Photoreactive ru (ii) complexes anchored on oligonucleotides, method for obtaining them and use thereof
Crean et al. Targeting of photooxidative damage on single-stranded DNA representing the bcr-abl chimeric gene using oligonucleotide-conjugates containing [Ru (phen) 3] 2+-like photosensitiser groups
CN114315791A (en) Small molecule chemiluminescence probe for realizing surgical navigation and imaging of micrometastases, and preparation method and application thereof
Huang et al. Enhancing mitochondria-targeted photodynamic therapy via synergistic mitophagy-ferroptosis by a peroxynitrite-activated near-infrared photosensitizer in triple-negative breast cancer
CN109745569B (en) Electrochromic material based H2S-activated probes and biological applications thereof
CN115998908A (en) Diagnosis and treatment integrated nucleic acid anchored fluorescent probe and preparation method and application thereof
CN102827209A (en) Application of ruthenium complex containing Hdppz ligand as singlet oxygen fluorescent probe
Guo et al. Multifunctional DNA nanosphere platform for real-time monitoring and fluorescence imaging-guided photodynamic therapy
Vuradi et al. Luminescent behavior of Ru (II) Polypyridyl morpholine complexes, synthesis, characterization, DNA, protein binding, sensor effect of ions/solvents and docking studies
Guo et al. A redox-activated Pt (IV) pro-probe: From G-quadruplex imaging to cancer therapy
Ortigao et al. Solid-phase introduction and intracellular photoinduced reaction of a water-soluble meso-tetracarboxyporphine conjugated to an antisens olligodeoxyribonucleotide
Carbonell et al. Acid–base behaviour and binding to double stranded DNA/RNA of benzo [g] phthalazine-based ligands
CN112111564A (en) Probe and preparation method and application thereof
CN116396283B (en) A carboxylesterase 2 recognition near-infrared fluorescent probe with large Stokes shift characteristics and its preparation method and application

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090825

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20100204

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20131001